Related Experiment Video
Updated: Jan 18, 2026

11:20
Retinal Pigment Epithelium Transplantation in a Non-human Primate Model for Degenerative Retinal Diseases
Published on: June 14, 2021
4.3K
PARS PLANA VITRECTOMY-SUPRACHOROIDAL VISCOPEXY FOR RHEGMATOGENOUS RETINAL DETACHMENT REPAIR.
Rajeev H Muni1,2,3, Isabela Martins Melo1,2, Shiva Sabour1,2
1Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada.
Retina (Philadelphia, Pa.)
|September 9, 2025
Summary
Pars plana vitrectomy-suprachoroidal viscopexy (VIT-SCVEXY) shows promising results for rhegmatogenous retinal detachment repair. This technique may offer a less invasive alternative to traditional scleral buckle surgery with comparable outcomes.
Area of Science:
- Ophthalmology
- Retinal Surgery
- Surgical Innovation
Background:
- Rhegmatogenous retinal detachment (RRD) is a serious condition requiring prompt surgical intervention.
- Traditional surgical repair often involves pars plana vitrectomy with scleral buckle (PPV-SB).
- Exploring less invasive techniques with comparable efficacy is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the reattachment rate of pars plana vitrectomy-suprachoroidal viscopexy (VIT-SCVEXY) for RRD repair.
- To compare the anatomic reattachment and functional outcomes of VIT-SCVEXY versus PPV-SB.
- To assess outcomes at 3 months postoperatively and at final follow-up.
Main Methods:
- Retrospective cohort study comparing VIT-SCVEXY (n=12) and PPV-SB (n=12) for RRD with inferior breaks.
- Patients were matched for key demographic and clinical characteristics.
- Outcomes assessed included retinal reattachment rates and best-corrected visual acuity (BCVA).
Main Results:
- Successful suprachoroidal viscoelastic buckle created in 75% of VIT-SCVEXY cases.
- 100% reattachment rate at 3 months for successful VIT-SCVEXY cases (9/9).
- Overall reattachment rates at 3 months were 100% for both VIT-SCVEXY (12/12) and PPV-SB (12/12).
- Final follow-up showed 91.6% reattachment for VIT-SCVEXY vs. 100% for PPV-SB (P=1.0).
- Mean BCVA was comparable between groups (LogMAR 0.7 ± 0.5 vs. 0.7 ± 0.3).
- Chemosis observed in 25% of VIT-SCVEXY cases; no adverse events in PPV-SB.
Conclusions:
- VIT-SCVEXY demonstrates comparable anatomic and functional outcomes to PPV-SB for RRD repair.
- VIT-SCVEXY may represent a less invasive surgical alternative.
- Further research is warranted to validate these findings and explore long-term outcomes.

